SCHEMBL29680450

SCHEMBL29680450

COCOc1cc(Cl)c(C2CC2)c(Br)c1

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 3/20 0.32
SLC6A4 P31645 1/20 0.32
MCHR1 Q99705 1/20 0.31
ROR1 Q01973 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23043281 1.00 HTR1A (0.32) HTR1ASLC6A4MCHR1ROR1
SCHEMBL31243107 0.85 HTR1A (0.31) HTR1ASLC6A4
SCHEMBL26207348 0.84 MAOA (0.37) HTR1ASLC6A4
SCHEMBL31328578 0.82
SCHEMBL30391527 0.82
SCHEMBL26197960 0.82
SCHEMBL31328741 0.82
SCHEMBL23043243 0.82
SCHEMBL29080087 0.82
SCHEMBL29014633 0.82 MCHR1 (0.31) HTR1AMCHR1ROR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025236100-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF Université de Montréal (CA) 2025-11-20 WO disclosed
EP-4626554-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF Tiger Biotherapeutics Inc. (US) 2025-10-08 EP disclosed
WO-2025151594-A1 FUSED AZINES AS RAS INHIBITORS AND METHODS OF USE THEREOF KESTREL THERAPEUTICS INC. (US) 2025-07-17 WO disclosed
CN-119923401-A Novel tetraheterocyclic compound 伊迪恩斯股份有限公司 2025-05-02 CN disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 EP disclosed
WO-2024118960-A1 GLUTARIMIDE-CONTAINING KRAS-MUTANT DEGRADER COMPOUNDS AND USES THEREOF TIGER BIOTHERAPEUTICS INC. (US) 2024-06-06 WO disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 WO disclosed
EP-4262807-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-10-25 EP disclosed
WO-2023125627-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LYNK PHARMACEUTICALS CO., LTD. (CN) 2023-07-06 WO disclosed
WO-2023284881-A1 HETEROCYCLIC COMPOUNDS USEFUL AS KRAS G12D INHIBITORS SILEXON AI TECHNOLOGY CO., LTD. (CN) 2023-01-19 WO disclosed
WO-2022262838-A1 DEUTERATED COMPOUNDS USEFUL AS KRAS G12D INHIBITORS SILEXON AI TECHNOLOGY CO., LTD. (CN) 2022-12-22 WO disclosed
WO-2022262686-A1 KRAS G12D INHIBITORS JINGRUI BIOPHARMA CO., LTD. (CN) 2022-12-22 WO disclosed
WO-2022132200-A1 AZAQUINAZOLINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2022-06-23 WO disclosed